key: cord-0872117-5bz8h843
authors: Khanna, Ashish K.; Jungquist, Carla R.; Buhre, Wolfgang; Soto, Roy; Di Piazza, Fabio; Saager, Leif
title: Modeling the Cost Savings of Continuous Pulse Oximetry and Capnography Monitoring of United States General Care Floor Patients Receiving Opioids Based on the PRODIGY Trial
date: 2021-05-24
journal: Adv Ther
DOI: 10.1007/s12325-021-01779-7
sha: f6285ab7e996c9fe3ebe76fba368b9221fd3c393
doc_id: 872117
cord_uid: 5bz8h843

INTRODUCTION: Despite the high incidence of respiratory depression on the general care floor and evidence that continuous monitoring improves patient outcomes, the cost–benefit of continuous pulse oximetry and capnography monitoring of general care floor patients remains unknown. This study modeled the cost and length of stay savings, investment break-even point, and likelihood of cost savings for continuous pulse oximetry and capnography monitoring of general care floor patients at risk for respiratory depression. METHODS: A decision tree model was created to compare intermittent pulse oximetry versus continuous pulse oximetry and capnography monitoring. The model utilized costs and outcomes from the PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY (PRODIGY) trial, and was applied to a modeled cohort of 2447 patients receiving opioids per median-sized United States general care floor annually. RESULTS: Continuous pulse oximetry and capnography monitoring of high-risk patients is projected to reduce annual hospital cost by $535,531 and cumulative patient length of stay by 103 days. A 1.5% reduction in respiratory depression would achieve a break-even investment point and justify the investment cost. The probability of cost saving is ≥ 80% if respiratory depression is decreased by ≥ 17%. Expansion of continuous monitoring to high- and intermediate-risk patients, or to all patients, is projected to reach a break-even point when respiratory depression is reduced by 2.5% and 3.5%, respectively, with a ≥ 80% probability of cost savings when respiratory depression decreases by ≥ 27% and ≥ 31%, respectively. CONCLUSION: Compared to intermittent pulse oximetry, continuous pulse oximetry and capnography monitoring of general care floor patients receiving opioids has a high chance of being cost-effective. TRIAL REGISTRATION: www.clinicaltrials.gov, Registration ID: NCT02811302. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-021-01779-7.

outcomes from the PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY (PRODIGY) trial, and was applied to a modeled cohort of 2447 patients receiving opioids per median-sized United States general care floor annually. Results: Continuous pulse oximetry and capnography monitoring of high-risk patients is projected to reduce annual hospital cost by $535,531 and cumulative patient length of stay by 103 days. A 1.5% reduction in respiratory depression would achieve a break-even investment point and justify the investment cost. The probability of cost saving is C 80% if respiratory depression is decreased by C 17%. Expansion of continuous monitoring to high-and intermediate-risk patients, or to all patients, is projected to reach a break-even point when respiratory depression is reduced by 2.5% and 3.5%, respectively, with a C 80% probability of cost savings when respiratory depression decreases by C 27% and C 31%, respectively. Conclusion: Compared to intermittent pulse oximetry, continuous pulse oximetry and capnography monitoring of general care floor patients receiving opioids has a high chance of being cost-effective. Respiratory depression occurs in 46% of patients receiving opioids on the general care floor, where standard of care monitoring consists of intermittent pulse oximetry spot-checks.

Continuous pulse oximetry and capnography monitoring can detect respiratory depression, but the cost-benefit of continuous pulse oximetry and capnography monitoring is unknown.

The purpose of this study was to model the cost and length of stay savings, investment break-even point, and likelihood of cost savings for continuous pulse oximetry and capnography monitoring of general care floor patients at risk for respiratory depression.

What was learned from the study?

Continuous pulse oximetry and capnography monitoring of high-risk patients could reduce annual hospital cost by $535,531 and cumulative patient length of stay by 103 days, reaching a break-even investment point when the incidence of respiratory depression decreases by 1.5%.

Compared to intermittent pulse oximetry, continuous pulse oximetry and capnography monitoring of general care floor patients receiving opioids has a high chance of being cost-effective.

Respiratory depression occurs when a person has an abnormally slow breath rate, low oxygen saturation, low or high concentration of exhaled carbon dioxide, or stops breathing intermittently. This condition occurs in 46% of patients receiving opioids in medical and surgical hospital units. Respiratory depression can be detected using continuous respiratory monitoring to measure respiratory rate, heart rate, blood oxygen saturation, and exhaled carbon dioxide. However, the cost-benefit of continuous respiratory monitoring in patients hospitalized in medical and surgical units is unknown. We created an economic model to predict differences in hospital cost and patient length of stay when using continuous respiratory monitoring, compared to intermittent blood oxygen saturation and heart rate monitoring. This model predicts the break-even point where the cost of investing in monitoring technology will equal the costs saved by preventing respiratory depression, and evaluates the chance that continuous respiratory monitoring will be cost saving. If patients at highest risk for respiratory depression are continuously monitored, the model projects annual hospital cost will decrease by $535,531, and total length of stay of all patients will decrease by 103 days. The cost of investing in monitoring is predicted to equal the cost savings if respiratory depression decreases by 1.5%, and there is a high probability of the investment being cost saving. The model also predicts that continuous monitoring will reduce annual cost and length of stay if patients at high and intermediate risk, or if all patients, undergo continuous respiratory monitoring. Overall, continuous respiratory monitoring has a high chance of being costeffective. This article is published with digital features,  including a summary slide and plain 

Respiratory depression is common on hospital general care floors, where nurses traditionally assess vital signs every 4-6 h [1] [2] [3] . However, compared to intermittent assessment of respiratory status, continuous electronic monitoring detects significantly more cardiorespiratory events [1, 4] . For example, 20% of all postoperative patients experience significant time under hypoxemic thresholds, and almost all go undetected with intermittent monitoring [1] . Low respiratory rate occurs in 41% of patients in the post-anesthesia care unit and general care floor [5] .

Recently, the PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY (PRODIGY) trial reported that 46% of postsurgical and medical patients receiving parenteral opioids experienced respiratory depression episodes [2] . This prospective trial comprehensively assessed respiratory depression, monitoring patients with blinded continuous pulse oximetry and capnography, including strict time and threshold cutoffs to define respiratory depression [2] . The PRODIGY trial found that adverse events requiring rescue action or prolonged hospitalization occurred more often in patients with monitor-detected respiratory depression episodes [2, 6] . This is consistent with prior reports using continuous pulse oximetry or capnography only [1, 5] , further substantiating that respiratory depression may be preventable with better monitoring and earlier intervention [2, 6, 7] .

Respiratory opioid-related adverse events (ORADE) are costly to healthcare systems [8] [9] [10] . In particular, unrecognized respiratory depression contributes to poor patient outcomes and longer lengths of stay that increase healthcare cost [6, [11] [12] [13] . Compared to United States (US) general care floor patients without respiratory depression, hospital cost is $3686 higher in patients with respiratory depression [6] . Although professional organizations and their clinical practice guidelines recommend the use of electronic respiratory monitoring, the majority of US hospitals do not have an adequate supply of devices [14, 15] . This is because despite current evidence that early recognition of respiratory depression can potentially decrease hospital cost, instituting continuous monitoring is perceived as requiring significant financial investment [16] .

The purpose of this analysis was to evaluate the economic value of continuous monitoring by modeling the investment break-even point and likelihood of cost savings with continuous pulse oximetry and capnography monitoring compared to intermittent pulse oximetry monitoring of general care floor patients receiving opioids.

A model was developed to estimate the investment break-even point and likelihood of cost savings associated with implementation of continuous pulse oximetry and capnography monitoring of US general care floor patients at risk for respiratory depression. The model, which follows good practice guidelines (International Society of Pharmacoeconomics and Outcomes Research) [17] , was created using a decision tree framework in Excel (Microsoft, Redmond, WA). The model considers a budget holder perspective for a median-sized US hospital and projects cost over a 1-year time horizon.

The model was created to compare costs and outcomes for (1) standard of care intermittent pulse oximetry monitoring versus (2) continuous respiratory monitoring with pulse oximetry and capnography of medical and surgical patients receiving opioids on the general care floor. Within the continuously monitored group, the model simulates outcomes for three scenarios: monitoring of patients at (1) high risk, (2) high and intermediate risk, or (3) any level (high, intermediate, or low) risk of respiratory depression, determined using the PRODIGY score ( Fig. 1 ) [2] . This model considers three PRODIGY trial outcomes: (1) incidence of respiratory depression episodes, (2) length of stay, and (3) total hospital admission costs. Owing to lack of interventional data, the effect of implementing continuous monitoring was modeled from 0% to 100% reduction in respiratory depression.

The PRODIGY trial enrolled 1495 patients age C 18, 20, and 21 across the USA and Europe, Japan, and Singapore, respectively. This post hoc analysis included only US patients who received parenteral opioids and underwent blinded continuous pulse oximetry and capnography monitoring on the general care floor (N = 758) [2, 18] . Continuous monitoring continued up to 48 h using the Capnostream TM 20p or 35 portable bedside monitor (Medtronic, Boulder, CO). The PRODIGY trial was conducted following institutional review board or ethics committee approval, with written informed consent collected from all patients. Respiratory depression episodes included respiratory rate B 5 breaths/minute, oxygen saturation B 85%, or end-tidal carbon dioxide B 15 or C 60 mmHg for C 3 min; apnea episode for [ 30 s; or any respiratory opioid-related adverse event [2, 18] . Each patient was retrospectively assessed for the risk of respiratory depression using the PRODIGY score, which was derived from the PRODIGY dataset using a multivariable logistic regression model [18] . The model includes five independent patient characteristics, including age C 60 in decades, male sex, sleep disordered breathing, opioid naivety, and chronic heart failure [2] . Each variable is assigned a point value, and patients can be easily evaluated for their risk of respiratory depression based on the sum of the points assigned, with low (\ 8 points), intermediate (C 8 and \ 15 points), and high (C 15 points) risk categories [2, 6] . Since the PRODIGY dataset was used to derive the PRODIGY score, for the purposes of this analysis, each PRODIGY patient was retrospectively assigned a PRODIGY score based on his or her age, sex, opioid naivety, and presence of sleep disordered breathing and chronic heart failure [6] .

Patients missing length of stay and hospital cost data (N = 11) or data required to determine PRODIGY score (N = 9) were excluded [6] . To determine the influence of patient outliers on the model, the analysis was performed using all patients with hospital costs available, and separately using a population excluding patient outliers for hospital cost or length of stay, identified using Cook's distance [6] .

The model extrapolates PRODIGY outcomes to a cohort of general care floor patients receiving opioids in a median-sized US hospital. On the basis of the 2018 Premier Ò Healthcare Database, 90% of surgical patients and 45% of medical patients on US general care floors receive opioids, with a median 2447 opioid-receiving patients per hospital per year (95% CI 2092-2802) ( Table S1 in Supplementary Material). This is consistent with recent literature [10, [19] [20] [21] [22] [23] .

Twenty percent (N = 171/835), 34% (N = 300/ 874), and 60% (N = 442/738) of the modeled cohort was allocated to low-, intermediate-, and high-risk respiratory depression groups, matching the PRODIGY trial distribution (Tables 1  and 2 ). PRODIGY cost and length of stay data were model inputs (Table 1 ) [6] . Discount rates, to determine net present value of costs and outcomes, and inflationary adjustments were not applied because of the model's short time horizon and the recency of the PRODIGY trial. The same model structure was applied separately utilizing inputs from the PRODIGY cohort excluding outliers (Table S2 in Supplementary Material) .

For intermittent pulse oximetry monitoring, device pricing consisted of a multiparameter monitor ($3000) prorated over 7 years and a reusable pulse oximetry sensor ($65). A US hospital with 27 opioid-receiving general care floor patients (Premier Ò Healthcare Database) would need three multiparameter monitors and two reusable pulse oximetry sensors per monitor, resulting in a device cost of $0.68 per patient stay. Continuous pulse oximetry and capnography device pricing consisted of a Capnostream TM portable respiratory monitor ($4300, Medtronic, Boulder, CO) prorated over 7 years, a Microstream TM capnography filterline In the base case, the percentage reduction in patients with C 1 respiratory depression episode was conservatively assumed at 20% reduction based on available literature, which reports a 34% risk reduction for intensive care unit (ICU) transfer upon implementation of continuous pulse oximetry monitoring, and reduction of severe opioid-related adverse events from 3.1/ 10,000 patients to 0.6/10,000 patients and a 50% decrease in rapid response calls due to opioid-induced respiratory depression following implementation of continuous capnography monitoring [16, 24, 25] . Break-even and sensitivity analyses did not rely on this assumption.

In the base case, the model evaluates annual hospital cost and cumulative patient length of stay using intermittent pulse oximetry monitoring of all general care floor patients receiving opioids, versus continuous pulse oximetry and capnography monitoring of general care floor patients with high respiratory depression risk receiving opioids (Fig. 1) . Additional scenarios evaluate the same outcomes, comparing intermittent pulse oximetry monitoring versus continuous respiratory monitoring of general care floor patients receiving opioids with high and intermediate respiratory depression risk, or any level respiratory depression risk. Break-even analysis simulated the minimum requirements needed to justify the investment, modeling cost and length of stay savings as a function of the percentage respiratory depression reduction from 0% to 100%.

Probabilistic sensitivity analysis was performed using 1000 Monte Carlo simulations [26] to determine the probability of continuous pulse oximetry and capnography monitoring being cost saving. The model estimates the investment break-even point and likelihood of cost savings when respiratory depression cases decrease from 0% to 100%. Parameters were assigned a probability distribution, including distinction of costs (gamma distribution), and epidemiological parameters (beta distributions), and accounted for the standard error of PROD-IGY dataset parameters. One-way deterministic sensitivity analysis was performed to examine the effects of model parameters on cost and length of stay outcomes. The uncertainty of each parameter was determined using variability estimated from the PRODIGY dataset.

Across all general care floor patients receiving opioids, continuous pulse oximetry and capnography monitoring of patients with high risk for respiratory depression would result in $535,531 annual savings and a cumulative length of stay decrease of 103 days per year (Table 2 ), compared to standard of care intermittent pulse oximetry monitoring. This assumes a 20% respiratory depression reduction and an annual general care floor volume of 2447 patients receiving opioids per mediansized hospital (Table S1 in Supplementary Material). In this scenario, the model predicts that a 1.5% reduction in respiratory depression would achieve an investment break-even point, with cost and length of stay savings increasing linearly as respiratory depression decreases ( Fig. 2a-b) . Reducing respiratory depression by 10%, 20%, and 30% would decrease hospital costs by $341, $726, and $1110 per patient, respectively (Fig. S1A in Supplementary Material).

A second scenario modeled the cost savings of continuously monitoring patients at high and intermediate respiratory depression risk with pulse oximetry and capnography, compared to intermittent pulse oximetry monitoring of all patients. In this scenario, cumulative patient length of stay would decrease by 152 days, with an annual savings of $606,463 ( Table 2 ). The reduction in respiratory depression required to reach a break-even point was 2.5% (Fig. 2a) .

The third scenario, in which all patients receiving opioids, regardless of risk for respiratory depression, undergo continuous respiratory monitoring, projected a cumulative length of stay savings of 204 days, with $688,221 in annual savings, compared to intermittent pulse oximetry monitoring of the same patients ( Table 2 ). The projected break-even point would occur when respiratory depression decreased by 3.5% (Fig. 2a) . These continuous monitoring scenarios are expected to linearly decrease perpatient cost and length of stay as respiratory depression decreases (Fig. S1A in Supplementary  Material, Fig. 2b ).

To evaluate the impact of patient outliers, a separate analysis was performed using the PRODIGY cohort excluding patient outliers. Compared to intermittent pulse oximetry monitoring on all patients, continuous pulse oximetry and capnography monitoring of patients with high respiratory depression risk would result in a 119-day reduction in cumulative length of stay and an annual hospital cost savings of $257,561 (Table S3 in Supplementary Material). A 3% reduction in respiratory depression would achieve an investment breakeven point (Fig. S2A in Supplementary Material), with a $355 per-patient cost savings if respiratory depression decreased 20% (Fig. S1B in Supplementary Material) . Similarly, the model excluding outliers predicts length of stay reductions of 183 and 216 days and annual (Table S3 in Supplementary Material). In these scenarios, the breakeven point would occur when respiratory depression decreases by 4-4.5%, with a linear decrease in length of stay as respiratory depression decreases (Fig. S2A-B in Supplementary Material).

To achieve a C 80% probability of cost savings when patients with high respiratory depression risk undergo continuous respiratory monitoring, a decrease in respiratory depression C 17% would be needed. This increases to a C 96% probability of cost savings if respiratory depression is decreased by C 30% (Fig. 3) . In scenarios in which continuous monitoring is applied to high-and intermediate-risk patients, or to all patients, a C 27% and C 31% reduction in respiratory depression would be needed to achieve a C 80% probability of being cost saving, respectively (Fig. 3) . Probabilistic sensitivity analysis of the model using the PRODIGY cohort excluding outliers projects that when patients with high, high or intermediate, or any respiratory depression risk undergo continuous monitoring, a respiratory depression decrease of C 27%, C 35%, and C 35%, respectively, would be needed to achieve a C 80% probability of being cost saving (Fig. S3 in Supplementary Material).

Model drivers were evaluated using one-way deterministic sensitivity analysis. For the model based on the PRODIGY cohort with outliers, admission cost of high-and intermediate-risk patients with respiratory depression had the strongest influence on model outcomes (Fig. S4A in Supplementary Material). Other drivers included the admission cost of high-and intermediate-risk patients without respiratory depression, the cost of low-risk patients with respiratory depression, and the number of general care floor patients receiving opioids per year. For the model excluding patient outliers, the main model drivers were similar (Fig. S4B in Supplementary Material). Monitoring device costs had a minimal influence on results.

Our analysis suggests that a reduction of C 1.5%, C 2.5%, and C 3.5% in respiratory depression episodes would justify the investment for continuous pulse oximetry and capnography monitoring when continuously monitoring high, high and intermediate, or all patients, respectively. Projected annual cost savings, assuming a 20% reduction in respiratory depression, would be $535,531 to $688,221, and reduction in cumulative length of stay would be 103-204 days annually, depending on the PRODIGY risk group(s) monitored. Furthermore, implementation of continuous respiratory monitoring has C 80% probability of being cost saving if respiratory depression is reduced by C 17%, C 27%, and C 31% if implemented on high-risk, high-and intermediate-risk, and all patients, respectively. Importantly, implementation of continuous monitoring alone will not decrease respiratory depression or adverse events, but can alert bedside providers to respiratory depression and facilitate early intervention. A true decrease in respiratory depression is dependent on how bedside providers respond to these alerts. Our analysis showed that the top model drivers include the cost burden of respiratory depression and general care floor volume, not the cost of monitoring equipment. This may be explained by the high cost of respiratory depression events. Specifically, monitoring equipment per patient may cost less to hospitals than a respiratory depression event, which sometimes leads to rapid response team activation and ICU transfer [6, 16] . The cost burden of surgical patients with ORADEs are reported to be $4350-8225 [10, 21, 27, 28] , representing a 27-47% increase in admission cost. This is consistent with the cost burden of respiratory depression observed in the PRODIGY trial, which were inputs in this model [6] .

We also evaluated the effect of patient outliers on modeling results. Model outcomes were consistent across both analyses, with a low break-even point for implementation of continuous respiratory monitoring and decreased annual cost and length of stay following reduction in respiratory depression.

This model has important implications for US hospital administrators, value and analysis committees, and clinical practice stakeholders (2) if the monitoring equipment is worth the investment for a subset of this patient population. A critical decision-making element for hospital administrators is identifying appropriate patients to monitor, to balance therapeutic benefit while limiting expenditure. Importantly, sensitivity analysis indicated that across the modeled scenarios, there is a high probability of continuous monitoring being cost saving, with the highest likelihood when monitoring high-risk patients. This analysis may be of particular value to cashstrapped hospitals needing to minimize equipment expenditure while maximizing patient safety.

The clinical utility of implementing continuous respiratory monitoring using pulse oximetry and capnography is supported by multiple studies. In one study, all postoperative patients who had respiratory depression requiring intervention were recognized by capnography, not by pulse oximetry [29] . Additionally, a systematic review and metaanalysis reported that compared to intermittent spot-check monitoring, continuous pulse oximetry decreased the risk of ICU transfer 34%, and SpO 2 \ 90% [ 1 h was 15 times more likely to be detected [24] . With continuous capnography monitoring, 8.6% more respiratory depression events were detected compared to pulse oximetry monitoring alone, and the odds of respiratory depression detection were 5.83 times higher using capnography vs pulse oximetry [24] .

The top strengths of this analysis include its real-world utility to hospital budget holders, its novelty in the literature, and its use of clinical trial data as the basis for the economic model. The hospital budget holder perspective, along with modeling a range of scenarios to minimize budget impact while maximizing patient safety, is pertinent since hospitals are likely to be in financial distress due to the Covid-19 pandemic. This work also adds novelty to the literature, in which we are not aware of any comparable models for respiratory depression. Finally, this model was created on the basis of PRODIGY trial data, which was the largest prospective observational trial of continuous multiparameter monitoring, where waveform data was collected in a blinded manner and subsequently evaluated by an independent adjudication committee.

Our work has some limitations. Our assumption of the number of patients per hospital does not apply to all hospitals. However, we used the Premier Ò database, which is one of the largest hospital-based discharge databases in the country, to determine the modeled cohort size and represent a median-sized US hospital. While this approach does represent all hospitals, a PRODIGY cost savings calculator to tailor this model to individual hospitals may be helpful but was beyond the scope of this analysis. Second, a 20% reduction in respiratory depression in the base case is supported by limited literature demonstrating reduced adverse events following implementation of continuous respiratory monitoring. Importantly, our sensitivity analysis eliminated this assumption and evaluated the likelihood of cost savings when all possible scenarios of respiratory depression reduction were modeled from 0% to 100%. Third, we assume that bedside providers will respond to continuous monitoring alerts, resulting in decreased incidence of respiratory depression, though data on response to continuous monitoring alerts is limited. This model did not include the cost of early intervention to prevent respiratory depression. Finally, the model is based on US PRODIGY patients only, which may limit the applicability of this model internationally, where opioid administration, standard of care practices, and hospital costs vary significantly [30] [31] [32] [33] .

Although intermittent monitoring has been standard of care for decades, continuous pulse oximetry and capnography monitoring detect more deviations of vital signs and has the potential to increase patient safety on the general care floor [1, 2, 24] . We assessed the investment cost-benefit ratio, and found that compared to intermittent pulse oximetry monitoring, continuous pulse oximetry and capnography monitoring of general care floor patients receiving opioids may be a cost-effective and worthwhile investment from the US hospital budget holder perspective. Our results suggest that limiting continuous monitoring to high-risk patients may be the least impactful to budgets, though expansion to intermediateand low-risk patients may offer good value considering the likely reduction in respiratory depression and associated costs.

Prior Presentation. A portion of this work was presented as an abstract at the Society for Technology in Anesthesia 2021 Virtual Annual Meeting.

Disclosures. Ashish K. Khanna, Carla R. Jungquist, Wolfgang Buhre, Roy Soto, and Leif Saager (or their institutions) received research support from Medtronic to conduct the PROD-IGY trial. In addition, Ashish K. Khanna Compliance with Ethics Guidelines. The PRODIGY trial was conducted following institutional review board or ethics committee approval for each trial site, and in accordance with the Helsinki Declaration of 1964 and its later amendments. The names of all review boards and ethics committees are provided in Table S4 of the Supplementary Material. Written informed consent was collected from all patients before participation in the trial.

Data Availability. All PRODIGY data generated or analyzed during this study are included in this published article/as supplementary information files. The data analyzed from the PremierÒ Healthcare Database were used under license for the current study and are not publicly available, but data may be available on reasonable request and with the permission of PremierÒ.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/bync/4.0/.

Critical revision of the manuscript for important intellectual content

Postoperative hypoxemia is common and persistent: a prospective blinded observational study

Prediction of opioid-induced respiratory depression on inpatient wards using continuous capnography and oximetry: an international prospective, observational trial

Risk factors for opioid-induced respiratory depression and failure to rescue: a review

Incidence, severity, and detection of blood pressure perturbations after abdominal surgery: a prospective blinded observational study

Continuous oximetry/capnometry monitoring reveals frequent desaturation and bradypnea during patient-controlled analgesia

Opioid-induced respiratory depression increases hospital costs and length of stay in patients recovering on the general care floor

Postoperative opioid-induced respiratory depression: a closed claims analysis

Cost of opioidrelated adverse drug events in surgical patients

The cost of opioid-related adverse drug events

The burden of opioid-related adverse drug events on hospitalized previously opioid-free surgical patients

Impact of pulse oximetry surveillance on rescue events and Adv Ther intensive care unit transfers: a before-and-after concurrence study

Validated model for predicting postoperative respiratory failure: analysis of 1706 abdominal wall reconstructions

Opioid prescription levels and postoperative outcomes in orthopedic surgery

Monitoring for opioidinduced advancing sedation and respiratory depression: ASPMN membership survey of current practice 2019

American Society for Pain Management nursing guidelines on monitoring for opioid-induced advancing sedation and respiratory depression: revisions

Continuous capnography reduces the incidence of opioid-induced respiratory rescue by hospital rapid resuscitation team

Consolidated health economic evaluation reporting standards (CHEERS)-explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force

Respiratory depression in low acuity hospital settings-seeking answers from the PRODIGY trial

Association of opioids and sedatives with increased risk of inhospital cardiopulmonary arrest from an administrative database

Marcantonio ER. Opioid utilization and opioid-related adverse events in nonsurgical patients in US hospitals

Association of opioid-related adverse drug events with clinical and cost outcomes among surgical patients in a large integrated health care delivery system

Patterns of opioid administration among opioidnaive inpatients and associations with postdischarge opioid use: a cohort study

Opiate use and escalation of care in hospitalized adults with acute heart failure and sleep-disordered breathing (OpiatesHF study)

Continuous pulse oximetry and capnography monitoring for postoperative respiratory depression and adverse events: a systematic review and meta-analysis

Impact of adoption of smart pump system with continuous capnography monitoring on opioid-related adverse event rates: experience from a tertiary care hospital

Decision modelling for health economic evaluation

Effect of opioid-related adverse events on outcomes in selected surgical patients

Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes

Capnography monitoring enhances safety of postoperative patient-controlled analgesia

Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study

Opioid utilization and perception of pain control in hospitalized patients: a cross-sectional study of 11 sites in 8 countries

Opioid prescribing after surgery in the United States, Canada, and Sweden

Health care spending in the united states and other high-income countries

We thank the participants of the PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY (PROD-IGY) trial for their valuable contributions.

Funding. Medtronic (Boulder, CO) sponsored the PRODIGY trial and this post hoc analysis, and funded Rapid Service Fees for publication in Advances in Therapy. The authors had final responsibility for the decision to submit for publication. The authors were not paid to write this article by the sponsor or any other agency.Medical Writing and/or Editorial Assistance. Biostatistical analysis was supported by Paola Di Stefano, MS (Medtronic, Rome, Italy). Rhodri Saunders, PhD of Coreva Scientific (Königswinter, North Rhine-Westphalia Germany) contributed to economic modeling. Medical writing support was provided by Katherine E. Liu, PhD (Medtronic, Minneapolis, MN, US) and supported by Medtronic.Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.